Efficacy of Amlodipine/Olmesartan ± Hydrochlorothiazide in Patients Uncontrolled on Prior Calcium Channel Blocker or Angiotensin II Receptor Blocker Monotherapy

被引:3
|
作者
Neutel, Joel [1 ]
Shojaee, Ali [2 ]
Maa, Jen-Fue [2 ]
机构
[1] Orange Cty Res Ctr, Dept Clin Pharmacol, Tustin, CA 92780 USA
[2] Daiichi Sankyo Inc, Parsippany, NJ USA
关键词
Amlodipine; Angiotensin II receptor blocker; Blood pressure; Calcium channel blocker; Combination therapy; Hydrochlorothiazide; Hypertension; Olmesartan medoxomil; OLMESARTAN MEDOXOMIL; BLOOD-PRESSURE; COMBINATION; AMLODIPINE; TRIAL;
D O I
10.1007/s12325-012-0030-z
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
While monotherapy is often recommended as initial treatment, most patients require dose escalation and add-on agents to achieve their blood pressure (BP) goal. This secondary analysis evaluated the efficacy and safety of initiating patients on a regimen of fixed-dose amlodipine (AML)/olmesartan medoxomil (OM) +/- hydrochlorothiazide (HCTZ) who were uncontrolled on prior monotherapy with a calcium channel blocker (CCB) or angiotensin II receptor blocker (ARB). Patients uncontrolled on prior monotherapy with CCB or ARB therapy were initiated on AML/OM 5/20 mg and up-titrated every 4 weeks to AML/OM 5/40 mg, AML/OM 10/40 mg, AML/OM 10/40 + HCTZ 12.5 mg, and AML/OM 10/40 + HCTZ 25 mg. Patients were up-titrated to a higher AML/OM dose if mean seated cuff BP (SeBP) was a parts per thousand yen120/70 mmHg, and up-titrated to any HCTZ dose if mean SeBP was a parts per thousand yen125/75 mmHg. The primary efficacy endpoint was the cumulative proportion of patients achieving a seated cuff systolic BP (SeSBP) goal of < 140 mmHg (< 130 mmHg for patients with diabetes) after 12 weeks. Secondary endpoints included mean change from baseline in SeBP and ambulatory BP, ambulatory BP target achievement, and safety. For the prior CCB (n = 118; baseline SeBP: 153.4/91.5 mmHg) and ARB (n = 237; 154.6/92.6 mmHg) groups, SeSBP goal achievement after 12 weeks was 72.7% and 76.9%, respectively. Mean changes (+/- SE) from baseline in SeBP were dose proportional for prior CCB and ARB patients, ranging from -9.9 (+/- 1.25)/-5.8 (+/- 0.83) mmHg and -13.9 (+/- 0.79)/-7.6 (+/- 0.47) mmHg at the AML/OM 5/20 mg dose, respectively, to -21.8 (+/- 1.68)/-11.6 (+/-.12) mmHg and -26.2 (+/- 1.31)/-15.0 (+/- 0.86) mmHg at the AML/OM 10/40 mg + HCTZ 25 mg dose (P < 0.0001 for all). An AML/OM-based titration regimen was efficacious in achieving BP goal in patients uncontrolled on prior monotherapy with a CCB or ARB.
引用
收藏
页码:508 / 523
页数:16
相关论文
共 50 条
  • [31] Renoprotective effect of a calcium channel blocker, benidipine, in combination with an angiotensin II receptor blocker in hypertensive patients with chronic kidney disease
    Dohi, Y.
    Miyagawa, K.
    Nakazawa, A.
    Kimura, G.
    JOURNAL OF HYPERTENSION, 2008, 26 : S515 - S515
  • [32] Effects of Exercise Therapy Alone and in Combination with a Calcium Channel Blocker or an Angiotensin Receptor Blocker in Hypertensive Patients
    Ohta, Masanori
    Tajiri, Yuji
    Yamato, Hiroshi
    Ikeda, Masaharu
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 2012, 34 (07) : 523 - 529
  • [33] Angiotensin II for Treatment of Calcium Channel Blocker Overdose
    Felzer, J. R.
    Hoskote, S. S.
    Chalmers, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [34] ANGIOTENSIN II RECEPTOR BLOCKER IS PREFERABLE TO CALCIUM CHANNEL BLOCKER TO IMPROVE NOCTURNAL DIPPING PATTERN IN UNTREATED HYPERTENSIVES
    Cho, Jin-Man
    Hwang, Hui-Jeong
    Jin, Eun-Sun
    Park, Chang-Bum
    Sohn, Il-Suk
    Kim, Chong-Jin
    JOURNAL OF CLINICAL HYPERTENSION, 2013, 15 (07): : 519 - 519
  • [35] Combination of direct rennin inhibitor - aliskiren, angiotensin II receptor blocker - valsartan, and calcium channel blocker - amlodipine, in therapy of hypertensive patient with gout (case report)
    Dralova, O. V.
    Maksimov, M. L.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2011, 7 (04) : 468 - 472
  • [36] Combined effects of calcium channel blocker and angiotensin II type 1 receptor blocker in hypertensive Dahl rats
    Yao, K
    Sonoda, R
    Ina, Y
    Ohno, T
    Sato, H
    Suzuki, K
    JOURNAL OF HYPERTENSION, 2002, 20 : S48 - S48
  • [37] Effect of an angiotensin II receptor blocker and a calcium channel blocker on hypertension associated penile dysfunction in a rat model
    Shimizu, Shogo
    Tsounapi, Panagiota
    Honda, Masashi
    Dimitriadis, Fotios
    Taniuchi, Keisuke
    Shimizu, Takahiro
    Inoue, Keiji
    Saito, Motoaki
    BIOMEDICAL RESEARCH-TOKYO, 2014, 35 (03): : 215 - 221
  • [38] Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan
    Jinno, T
    Iwai, M
    Li, Z
    Li, JM
    Liu, HW
    Cui, TX
    Rakugi, H
    Ogihara, T
    Horiuchi, M
    HYPERTENSION, 2004, 43 (02) : 263 - 269
  • [39] Angiotensin II receptor blocker combined with eplerenone or hydrochlorothiazide for hypertensive patients with diabetes mellitus
    Karashima, Shigehiro
    Yoneda, Takashi
    Kometani, Mitsuhiro
    Ohe, Masashi
    Mori, Shunsuke
    Sawamura, Toshitaka
    Furukawa, Kenji
    Yamagishi, Masakazu
    Takeda, Yoshiyu
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 2016, 38 (07) : 565 - 570
  • [40] The velocity of antihypertensive effect of losartan/hydrochlorothiazide and angiotensin II receptor blocker
    Metoki, Hirohito
    Ohkubo, Takayoshi
    Kikuya, Masahiro
    Asayama, Kei
    Inoue, Ryusuke
    Obara, Taku
    Hirose, Takuo
    Sato, Michihiro
    Hashimoto, Takanao
    Imai, Yutaka
    JOURNAL OF HYPERTENSION, 2012, 30 (07) : 1478 - 1486